Rontalizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IFN-α |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6486H9990N1722O2026S44 |
| Molar mass | 145917.93 g·mol−1 |
  (what is this?) (verify) | |
Rontalizumab is a humanized monoclonal antibody[1] being developed by Genentech.[2] As of November 2009, it is being investigated in a clinical trial for the treatment of systemic lupus erythematosus.[3][4]
References
- ↑ WHO Drug Information
- ↑ Genentech: Rontalizumab (rhuMAb IFN alpha)
- ↑ Clinical trial number NCT00962832 for "A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (ROSE)" at ClinicalTrials.gov
- ↑ Misra DP, Negi VS (March 2017). "Interferon targeted therapies in systemic lupus erythematosus". Mediterranean Journal of Rheumatology. 28 (1): 13–19. doi:10.31138/mjr.28.1.13. PMC 7045923. PMID 32185249.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.